CHOSA Oncology
CHOSA Oncology AB's postpones publication of the interim report Q2
REG
The company's performance throughout the second quarter has aligned with expectations and remains in accordance with the established financial plan. Operations have been executed in line with projections, and current funding is secured through the second quarter of 2024. The delay in publishing the quarterly report is attributed solely to unforeseen administrative circumstances that fall beyond the scope of the Company's control.
This disclosure contains information that Chosa Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-08-2023 18:51 CET.
| Datum | 2023-08-27, kl 18:51 |
| Källa | Cision |
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.